Nautilus Biotechnology (NAUT) Q3 2024 earnings summary

Executive summary

• The company is developing a single-molecule proteome analysis platform targeting >95% of the human proteome, with significant progress in proteoform detection, especially tau, and strategic collaborations in oncology, rare diseases, and drug discovery.

• The platform leverages machine learning and proprietary reagents, aiming for disruptive impact in a $55B+ market by 2027, but remains in the development and collaboration phase with no commercial products or revenue to date.

• Commercial launch is targeted for late 2025, with early access programs, proteoform collaborations, and in-house data production planned to precede launch.

• Customer and market feedback highlight strong demand for both targeted and broad-scale proteomics, with pharma and academic interest accelerating.

• The company is positioned as a first mover with a disruptive technology, supported by a robust patent portfolio and proven commercial model.

Financial highlights

• Q3 2024 net loss was $16.4 million, with operating expenses of $19.1 million, both flat year-over-year; net loss for the nine months ended September 30, 2024 was $53.2 million.

• Research and development expenses were $12.3 million for Q3 2024 and $37.7 million for the nine months ended September 30, 2024.

• Cash, cash equivalents, and investments totaled $221.2 million as of September 30, 2024, with cash burn of $11.7 million in Q3 2024.

• No revenue was generated in the reporting period.

• Cash runway extends into 2027 due to lower-than-expected expense growth and higher cash balance.

Outlook and guidance

• Commercial launch of the proteome analysis platform is anticipated in late 2025, with early access and proteoform collaborations to precede launch.

• Operating expense growth for full year 2024 is expected at ~10%, better than previous guidance.

• The company expects to continue incurring significant losses as it advances R&D and prepares for commercialization.

• Current cash and investments are expected to fund operations for at least the next 12 months, but additional capital will likely be needed for long-term growth.

• Focus remains on tight spend management and prioritization to support product milestones and commercial launch.